Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
Provided herein are compositions, methods and kits for a CCR9-mediated disease in a mammal in need thereof. The method include administering to a subject with a CCR9-mediated disease a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-TNFα antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-TNFα antibody.
1 . A method of treating a CCR9-mediated disease in a mammal, said method comprising administering a suitable amount of a CCR9 inhibitor with an anti-TNFα blocking antibody, wherein the CCR9 inhibitor is Compound 1
2 . The method of claim 1 , wherein the CCR9-mediated disease is gastrointestinal graft versus host disease (gvhd), autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency (ALPS type 5), immunodysregulation, polyendocrinopathy and enteropathy X-linked (IPEX), primary sclerosing cholangitis (PSC), autoimmune gastrointestinal dysmotility (AGID), autosomal recessive early-onset inflammatory bowel disease, collagenous gastritis (CG), satoyoshi syndrome, or sclerosing mesenteritis.
3 . The method of claim 1 , wherein the anti-TNFα blocking antibody is infliximab, adalimumab, golimumab, certolizumab pegol, or a biosimilar bioequivalent thereof.
4 . The method of claim 1 , wherein the CCR9 inhibitor and the anti-TNFα blocking antibody are administered in a combination formulation.
5 . The method of claim 1 , wherein the CCR9 inhibitor and the anti-TNFα blocking antibody are administered sequentially.
6 . The method of claim 5 , wherein the CCR9 inhibitor is administered prior to the anti-TNFα blocking antibody.
7 . The method of claim 5 , wherein the CCR9 inhibitor is administered after administration of the anti-TNFα blocking antibody.
8 . The method of claim 1 , wherein the anti-TNFα blocking antibody is infliximab, or a biosimilar, or bioequivalent thereof.
9 . The method of claim 1 , wherein the anti-TNFα blocking antibody is adalimumab, or a biosimilar or bioequivalent thereof.
10 . The method of claim 1 , wherein the anti-TNFα blocking antibody is golimumab, or a biosimilar or bioequivalent thereof.
11 . The method of claim 1 , wherein the anti-TNFα blocking antibody is certolizumab pegol, or a biosimilar or bioequivalent thereof.
12 . A composition for treating disease CCR9-mediated disease in a mammal, said composition comprising a therapeutically effective amount of a CCR9 inhibitor, a therapeutically effective amount of an anti-TNFα blocking antibody, and a pharmaceutically acceptable carrier or excipient, wherein the CCR9 inhibitor is Compound 1
13 . The composition of claim 12 , wherein the anti-TNFα blocking antibody is infliximab, adalimumab, golimumab, or a biosimilar or bioequivalent thereof.
14 . The composition of claim 12 , wherein the CCR9-mediated disease is gastrointestinal graft versus host disease (gvhd), autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency (ALPS type 5), immunodysregulation, polyendocrinopathy and enteropathy X-linked (IPEX), primary sclerosing cholangitis (PSC), autoimmune gastrointestinal dysmotility (AGID), autosomal recessive early-onset inflammatory bowel disease, collagenous gastritis (CG), satoyoshi syndrome, or sclerosing mesenteritis.
15 . A kit for treating a CCR9-mediated disease in a mammal, said kit comprising a therapeutically effective amount of a CCR9 inhibitor, and a therapeutically effective amount of an anti-TNFα blocking antibody, with instructions for effective administration, wherein the CCR9 inhibitor is Compound 1
16 . The kit of claim 15 , wherein the CCR9 inhibitor and the anti-TNFα blocking antibody are formulated for sequential administration.
17 . The kit of claim 15 , wherein the CCR9 inhibitor and the anti-TNFα blocking antibody are formulated for concomitant administration.
18 . The kit of claim 15 , wherein the CCR9-mediated disease is gastrointestinal graft versus host disease (gvhd), autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency (ALPS type 5), immunodysregulation, polyendocrinopathy and enteropathy X-linked (IPEX), primary sclerosing cholangitis (PSC), autoimmune gastrointestinal dysmotility (AGID), autosomal recessive early-onset inflammatory bowel disease, collagenous gastritis (CG), satoyoshi syndrome, or sclerosing mesenteritis.